Transcranial magnetic stimulation (TMS) produces meaningful improvement in roughly 44% of people with depression, and about 38% achieve full remission. Those numbers come from real-world clinical data, not best-case scenarios, and they represent people who had already tried antidepressant medication without adequate relief. For a treatment targeting one of the hardest-to-treat populations in psychiatry, those rates are significant.
Response and Remission Rates
The two numbers that matter most when evaluating any depression treatment are response rate (a substantial reduction in symptoms, typically 50% or more) and remission rate (symptoms dropping low enough to no longer qualify as clinical depression). In clinical practice, TMS achieves a response rate of about 44% and a remission rate of about 38% across all severity levels.
Depression severity makes a real difference in outcomes. People with mild-to-moderate depression see remission rates around 60%, while those with severe depression see rates closer to 19%. Response rates follow a similar pattern: 55% for mild-to-moderate cases versus 33% for severe cases. Even among those who don’t fully remit, most patients experience measurable symptom reduction. People with mild-to-moderate depression improved by about 49% on standardized depression scales, and those with severe depression improved by about 41%.
These numbers are especially notable when you consider that TMS patients have typically already failed at least one antidepressant. This is not a first-line population where high placebo responses inflate the data. These are people for whom standard treatment didn’t work.
How TMS Works in the Brain
TMS uses focused magnetic pulses to stimulate a region on the left side of the brain’s outer surface called the dorsolateral prefrontal cortex. In people with depression, this area is consistently underactive, and its weakened connection to deeper emotional-processing regions contributes to the persistent low mood, loss of motivation, and difficulty concentrating that characterize the condition.
High-frequency pulses delivered to the left side of this region increase neural activity there, essentially waking up circuits that have gone quiet. Low-frequency pulses to the right side can also help by calming overactive circuits linked to both depression and anxiety. Over repeated sessions, these pulses strengthen the connections between neurons in ways that outlast the stimulation itself. This process, called synaptic plasticity, is the opposite of what depression does to the brain: where depression weakens neural connections, TMS rebuilds them.
Brain imaging studies show that TMS also increases blood flow to the stimulated area, and the degree of that blood flow increase correlates with better treatment outcomes. There’s also preliminary evidence that TMS may promote the growth of new brain cells, though that research is still in early stages.
What a Treatment Course Looks Like
A standard TMS course involves five sessions per week for four to six weeks, totaling 30 to 36 sessions. Each session of standard repetitive TMS lasts 20 to 40 minutes. A newer protocol called theta-burst stimulation delivers the same therapeutic effect in just 3 to 10 minutes per session. Clinical trials have confirmed that theta-burst stimulation is equally effective as standard TMS, with comparable results lasting at least 26 weeks.
You sit in a chair, fully awake, with no anesthesia or sedation. A technician positions a magnetic coil against your scalp and delivers pulses that feel like rapid tapping. You can drive yourself home afterward and return to normal activities immediately. There’s no recovery period and no cognitive fog. Many people schedule sessions before work or during a lunch break.
Side Effects and Safety
TMS has a mild side-effect profile compared to most depression treatments. The most common complaint is headache, reported by about 7 to 10% of patients, followed by discomfort at the stimulation site in roughly 3 to 9%. These tend to be mild and diminish over the first few sessions as patients acclimate.
Serious adverse events are rare, occurring in about 1.5% of patients. Seizures happen in fewer than 1% of cases. Other uncommon serious events include induction of a manic-like state and, very rarely, hearing changes. Because the treatment is noninvasive and doesn’t require anesthesia, it avoids the weight gain, sexual dysfunction, fatigue, and emotional blunting that drive many people away from antidepressant medications.
How Long Results Last
One of the most common concerns about TMS is whether the improvement sticks. Data from accelerated deep TMS protocols show that about 93% of patients who responded to treatment maintained their improvement at six months. That’s an encouraging durability figure, though individual experiences vary. Some people sustain their gains for a year or more, while others notice a gradual return of symptoms and benefit from periodic maintenance sessions or a shorter retreatment course.
Who Qualifies for TMS
The FDA first cleared TMS for adults with major depressive disorder who haven’t responded adequately to antidepressant medication, and more recently expanded clearance to include adolescents aged 15 to 21. Insurance coverage, including Medicare, typically requires a confirmed diagnosis of severe major depressive disorder plus documented failure of at least one antidepressant trial (meaning either the medication didn’t work or caused intolerable side effects).
In practice, many insurance plans require documentation of one or more failed medication trials before they’ll approve coverage. If you’ve tried an antidepressant that didn’t help or that you couldn’t tolerate, you likely meet the basic threshold. Your provider will need to submit clinical documentation, and approval timelines vary by insurer, but the criteria are less restrictive than they were even a few years ago.
Severity Matters More Than Most People Realize
The single biggest predictor of TMS success that patients can actually understand is where they fall on the depression severity spectrum. A 60% remission rate for mild-to-moderate depression versus 19% for severe depression is a threefold difference. This doesn’t mean people with severe depression shouldn’t try TMS. A 33% response rate still represents meaningful relief for a third of patients who have run out of other options. But it does mean that pursuing TMS earlier, before depression deepens and becomes more entrenched, may improve your odds considerably. If your first antidepressant isn’t working well, TMS is worth discussing with your provider sooner rather than later.